Clinical Trial

Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a multi-national, open-label, randomized, seamless phase II/III clinical study of UTD2 combined with fluoropyrimidine- and platinum-containing therapy to evaluate the efficacy and safety in patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma untreated with systemic treatment in advanced setting.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-18.
Status change: Not Yet Recruiting → Recruiting 2025-11-20
Trial Details
NCT Number NCT06841679
Lead Sponsor Beijing Biostar Pharmaceuticals Co., Ltd.
Conditions Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment 778 participants
Start Date 2025-08-28
Primary Completion 2030-09-01 (estimated)
Study Completion 2030-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-25